Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70612 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Kimitoshi Nakamura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Enzyme Replacement Therapy, Mucopolysaccharidosis II, Iduronate Sulfatase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: JCR Pharmaceuticals, Keio University.
Abstract (Originalsprache)
Aims
Enzyme replacement therapy (ERT) for mucopolysaccharidosis II (MPS II) requires long‐term, weekly intravenous infusions often lasting over 3 h each time, which can burden paediatric patients and caregivers and negatively affect their quality of life and treatment compliance. The aim of this study was to assess whether shortening infusion duration impacts the long‐term efficacy and safety of ERT.
Methods
A post hoc analysis was conducted using 260 weeks of clinical data from 27 Japanese patients with MPS II who received pabinafusp alfa at a dose of 2.0 mg/kg/week during a Phase II/III clinical trial and an extension study. Individual adjustments to the weekly infusion duration were allowed only during the extension study. Safety was assessed through the incidence of adverse events and infusion‐associated reactions, while efficacy was evaluated by measuring heparan sulfate and dermatan sulfate levels in the cerebrospinal fluid (CSF), serum and urine, as well as assessing liver and spleen volumes and neurocognitive development scores.
Results
Shorter infusion times were not associated with increased infusion‐associated reactions or other adverse events. Heparan sulfate and dermatan sulfate levels in the CSF, serum and urine, as well as liver and spleen volumes were not affected by changes in infusion rates, indicating sustained therapeutic efficacy.
Conclusions
Infusion rate adjustments were not associated with notable changes in the safety or efficacy of ERT with pabinafusp alfa in patients with MPS II. Clinicians may safely consider decreasing infusion times on a case‐by‐case basis to improve patients' quality of life and treatment compliance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.
- ISEIKAI International General Hospital, Osaka, Japan.
- JCR Pharmaceuticals, Ashiya, Japan.
ORCID-Profile: Yuji Sato
Förderung
- JCR Pharmaceuticals
- Keio University
Zitieren
APA
Nakamura, K., Sakai, N., Hirai, H., Takasao, N., Ibaraki, R., Yamamoto, T., & Sato, Y. (2026). Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70612
Vancouver
Nakamura K, Sakai N, Hirai H, Takasao N, Ibaraki R, Yamamoto T, et al. Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70612
BibTeX
@article{Nakamura2026,
author = {Nakamura, Kimitoshi and Sakai, Norio and Hirai, Hideaki and Takasao, Naoko and Ibaraki, Ryo and Yamamoto, Tatsuyoshi and Sato, Yuji},
title = {Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70612}
}
EUVIMED